19th Aug 2025 07:00
19 August 2025
ANANDA PHARMA PLC
("Ananda" or the "Company")
Webinar Presentation Release
Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that the post annual report corporate update presentation delivered on 12 August 2025 has been posted to the Company's website and is available to read here: https://investors.anandapharma.co.uk/webinars/WPGNwr-post-annual-report-corporate-update-and-q-a.
At this link, it will be possible to watch a recording of the presentation and ask a question which will be responded to, on the Company's Investor Hub, by management.
The Company's CEO and the presenter, Melissa Sturgess, said: 'It's a decent feeling to signpost our achievements over the past 12 months and highlight our objectives for the next 6 months.Our achievements include:- raising £2.38m from new and existing shareholders- being confirmed as the supplier of our MRX2 CBD & MRX2T CBD/THC formulations to two Phase 3a placebo controlled clinical trials into epilepsy- the appointment as Advisors of 2 ex senior GW Pharmaceuticals executives- Ethics Approval granted for our Phase 1 pharmacokinetic study in Australia- delivery of MRX1 CBD to the trial site in Australia- commencement of dosing in the Phase 1 study in AustraliaAll this is in the quest to get our MRX1 CBD through clinical trials and FDA regulatory approvals.It's a reasonably short 20min update and 10 min of Q&A. We hope you find it useful.'
About Ananda Pharma
Ananda Pharma (AQSE: ANA, OCT: ANANF) is a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR). The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.
For more information, please visit our website:
To stay up to date with Ananda's news please follow our social media channels:
· Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93
· Instagram: https://www.instagram.com/anandapharmaplc/
· LinkedIn: https://www.linkedin.com/company/anandapharma
· X: https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor
-Ends-
ANANDA PHARMA PLC | +44 (0)7463 686 497 |
| |
Chief Executive Officer | |
Melissa Sturgess | |
Finance Director | |
Jeremy Sturgess-Smith | |
| |
SP ANGEL CORPORATE FINANCE LLP | |
| |
Corporate Finance | +44 (0)20 3470 0470 |
Richard Morrison | |
Josh Ray | |
| |
Corporate Broking | +44 (0)20 3470 0534 |
Vadim Alexandre | |
Abigail Wayne | |
Rob Rees
| |
VIRIDIAN CAPITAL ADVISORS (US) Scott Greiper | +1 (646) 330-0704
|
YELLOW JERSEY PR Sarah MacLeod Charles Goodwin Zara McKinlay | +44 (0)20 3004 9512
|
https://investors.anandapharma.co.uk/link/P76mKr
Related Shares: